With data to propel it into PhIII, 89bio asks market for nearly $100M to bankroll ex-Teva drug

Kyle LaHucik

Associate Editor

89bio, born out of a Teva drug, is the latest to board the speed rail that takes biotechs from positive clinical data drop to cash request within a minute.

The San Francisco biotech revealed a mid-stage test that passed muster in a high-fat condition that sometimes leads to cardiovascular disease, and a minute afterwards in a Tuesday post-market release, 89bio asked investors for $75 million. Hours later, past midnight, they upsized the public offering to $94.5 million.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

With data to propel it into PhIII, 89bio asks market for nearly $100M to bankroll ex-Teva drug

Kyle LaHucik

Associate Editor

Unlock this article instantly by becoming a free subscriber.

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them

With da­ta to pro­pel it in­to PhI­II, 89bio asks mar­ket for near­ly $100M to bankroll ex-Te­va drug

Kyle LaHucik

Associate Editor

Unlock this article instantly by becoming a free subscriber.

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

5 Pa­tient En­gage­ment & Re­cruit­ment Trends, and How to Keep Up with Them

With data to propel it into PhIII, 89bio asks market for nearly $100M to bankroll ex-Teva drug

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them